Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Otsuka, GW Pharmaceuticals Sign Joint Research Agreement
July 23, 2007
- Wyeth Japan Committed to Catching Up with the Rest of the World
July 23, 2007
- REGULATORY NEWS IN BRIEF
July 23, 2007
- Price Agreement Rate Rose to 92.4% as of End of March
July 23, 2007
- Exelon Patch Approved for Alzheimer's Disease: Novartis
July 23, 2007
- R&D NEWS IN BRIEF
July 23, 2007
- Promote Multinational Clinical Trials to Eliminate Drug Lag: Study Group
July 23, 2007
- NEW PRODUCTS
July 23, 2007
- Profits Should Be Transferred from Long-Listed Drugs to New Drugs: Mr Yamabe
July 23, 2007
- New CRT-D Concerto C154DWK, ICD Virtuoso VR: Medtronic
July 23, 2007
- JPMA Proposes “Reported Price Approval System” for New Drugs
July 23, 2007
- EnRhythm Automatically Selects Optimal Pacing Mode: Medtronic
July 23, 2007
- Industry Presents NHI Pricing System Reform Proposals to Health Minister
July 23, 2007
- Cook Conducts Joint Clinical Trial of Zilver PTX Stent in Japan and US
July 23, 2007
- GENERICS NEWS IN BRIEF
July 23, 2007
- Asahi Kasei Medical, Kuraray Medical to Merge Dialysis Business First
July 23, 2007
- Increases in DPC Hospitals Drive Nichi-Iko's Business
July 23, 2007
- MEDICAL DEVICE NEWS IN BRIEF
July 23, 2007
- Nippon Chemiphar to Drastically Shift Priority to Generics
July 23, 2007
- Number of Patients Enrolled in Avastin PMS Exceeds 500 in 1 Month: Chugai
July 23, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…